Legend Capital
Mr. Yang joined Legend Capital in 2011 as Associate and was later promoted to Vice President and Director. Now he is an Executive Director of the firm and focuses on Health Care sector.
Max led or participated in investments of Chemclin Diagnostics, NOVAST Laboratories, Genext Medical Technology, DEEP INFORMATICS++, Kingmed Diagnostics(603882.SH), WUXIAPPTEC(603529.SH/02359.HK), Pharmaron(300759.SZ/03759.HK), SHCELL, etc.
Prior to Legend Capital, Mr. Yang worked with Sony China.
He received his Bachelor’s degree in Business Management from Tongji University and NEOMA Business School – CESEM, and Advanced Master degree in Strategy & Management of International Business from ESSEC Business School.
This person is not in any offices
Legend Capital
1 followers
In April 2001, Legend Capital was formed, and set up its first fund with US$35 mn commitment from Legend Holdings. Now Legend Capital is the independent Venture Capital investment subsidiary under the holdings company. In February 2012, Legend Capital took the new Chinese name "君联(Junlian)".